Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
7 No-Brainer Biotech Stocks to Add to Your Buy List
09:58am, Thursday, 09'th Jun 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
12:51pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disea
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
10:32am, Tuesday, 07'th Jun 2022
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disea
Why Shares of Sage Therapeutics Climbed 15.6% This Week
10:20pm, Friday, 03'rd Jun 2022 The Motley Fool
Investors can see the finish line for the company's second marketed therapy.
If You Invested $10,000 in Eli Lilly 10 Years Ago, This Is How Much You Would Have Today
10:00am, Friday, 03'rd Jun 2022 The Motley Fool
Is the stock a buy today?
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS
09:20am, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced new 12-month data for tofersen, an investigational antisense drug for people with superoxide dismutase
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
07:20pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
04:33pm, Thursday, 02'nd Jun 2022
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?
03:31pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Beaten-Down Cathie Wood Stocks That Look Like Bargains
12:21pm, Thursday, 02'nd Jun 2022 The Motley Fool
These stocks are all down more than 70% from their 52-week highs.
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
06:39pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
01:00pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start late
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
10:32am, Wednesday, 01'st Jun 2022
Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start late
Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension
06:31pm, Tuesday, 31'st May 2022 Zacks Investment Research
The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.
Wide-Moat Stocks On Sale - The June 2022 Heat Map
07:20am, Tuesday, 31'st May 2022 Seeking Alpha
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison.
